Peter Attia MD

Peter Attia, MD, says he is asked about Ozempic (semaglutide) almost daily by friends, acquaintances and patients. He describes it as a GLP-1 agonist and the prototype weight loss drug right now, with Wegovy being the brand name used for weight loss.

1. 0:01 Introduction
2. 1:26 Food noise and cravings
3. 2:41 Weigh-in and results
4. 4:03 The trials

• Side effects mentioned: low appetite
• Who is speaking: Clinician, MD

In this clip from a Peter Attia MD video featuring Rhonda Patrick, Ph.D., the physician describes how his practice now approaches tirzepatide. He says about 15 to 20% of his patients are on it.

1. 0:00 Managing muscle on GLP-1s
2. 1:33 Dosing and weight loss strategy
3. 3:02 Health risks and considerations
4. 4:21 Metabolic benefits without weight loss
5. 7:05 Injection sites and future research

• Doses mentioned: 2.5 mg, 7.5 mg and 10 mg
• Side effects mentioned: muscle loss
• Who is speaking: Clinician, MD

This is a sneak peek of an Ask Me Anything episode from Peter Attia's podcast. Attia, with a co-host, sets up two topics: GLP-1 drugs and metformin as a geroprotective agent.

1. 0:00 Intro
2. 0:08 The hype around semaglutide, tirzepatide, and other GLP-1 ag
3. 4:09 Overview of GLP-1 agonists and why these drugs are getting s
4. 12:20 Defining the term “geroprotective”
5. 14:08 Semaglutide: background, brand names, indications, and more
6. 19:10 Tirzepatide: background, brand names, indications, and more

• Doses mentioned: 2 mg, 2.4 mg and 15 mg
• Who is speaking: Clinician, MD

Dr. Ralph DeFronzo answers a question about long-term safety of the current generation of GLP-1 drugs. He says that at present he considers these drugs quite safe, with the main practical issue being gastrointestinal toxicity, which means dosing has to go slowly.

1. 0:00 Safety and the pipeline
2. 0:37 Weight loss and muscle mass
3. 2:17 Functional gains in strength
4. 4:35 Myostatin inhibitors
5. 6:42 Clinical trial criteria
6. 8:39 Redefining functional tests
7. 9:39 Pharmacological vs exercise

• Side effects mentioned: muscle loss
• Who is speaking: Clinician, MD

Peter Attia, the channel's host, describes a conversation he had the day before with a patient about starting a GLP-1 agonist. He says she is in her early to mid-40s, healthy and active, and by her own estimate about 15 lb overweight.

1. 0:37 Alcohol
2. 1:46 Stopping and maintenance
3. 3:39 Wrapping up

• Who is speaking: Clinician, MD

In this excerpt from a conversation, Peter Attia says he has noticed a consistent pattern in patients who take GLP-1 agonists and the dual GLP-1/GIP agonists.

1. 0:00 Glp-1 effect on heart rate
2. 1:33 Vagus nerve and appetite
3. 2:53 Risk assessment of drugs
4. 3:53 Impact on nervous system
5. 5:02 Reversibility of effects
6. 6:21 Stimulants and stress

• Side effects mentioned: low appetite
• Who is speaking: Clinician, MD

In this clip from Peter Attia MD's channel, Anna Lembke is asked about the link between gastric bypass and alcohol problems, and then about whether GLP-1 agonists such as semaglutide might help people with addiction.

1. 0:00 Bypass and alcoholism
2. 0:35 Addiction transfer
3. 2:01 GLP-1 agonists
4. 3:04 Clinical observations
5. 3:59 Addiction treatment options
6. 5:59 Case study
7. 7:24 Future of addiction drugs

• Who is speaking: Clinician, MD